The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Zanaflex 4 mg Tablets



Teva Pharma B.V.PA0749/054/002

Main Information

Trade NameZanaflex 4 mg Tablets
Active SubstancesTizanidine
Dosage FormTablet
Licence HolderTeva Pharma B.V.
Licence NumberPA0749/054/002

Group Information

ATC CodeM03BX Other centrally acting agents
M03BX02 tizanidine

Status

License statusAuthorised
Licence Issued25/01/2008
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back